Welcome to LookChem.com Sign In|Join Free
  • or
3-Methylamino-1-butyne, also known as 3-methylaminobut-1-yne, is an organic compound with the chemical formula C5H9N. It is a colorless liquid with a pungent odor and is used as a chemical intermediate in the synthesis of various pharmaceuticals and agrochemicals. 3-METHYLAMINO-1-BUTYNE is characterized by its unique structure, featuring a triple bond between the first and second carbon atoms, a methyl group attached to the third carbon, and an amino group on the third carbon as well. Due to its reactivity, 3-methylamino-1-butyne requires careful handling and storage to prevent unwanted reactions or decomposition.

4070-90-0

Post Buying Request

4070-90-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

4070-90-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 4070-90-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,0,7 and 0 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 4070-90:
(6*4)+(5*0)+(4*7)+(3*0)+(2*9)+(1*0)=70
70 % 10 = 0
So 4070-90-0 is a valid CAS Registry Number.

4070-90-0Relevant academic research and scientific papers

NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

-

Page/Page column 128, (2015/06/25)

The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.

Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's disease

Huleatt, Paul B.,Khoo, Mui Ling,Chua, Yi Yuan,Tan, Tiong Wei,Liew, Rou Shen,Balogh, Balázs,Deme, Ruth,G?l?ncsér, Flóra,Magyar, Kalman,Sheela, David P.,Ho, Han Kiat,Sperlágh, Beáta,Mátyus, Péter,Chai, Christina L. L.

supporting information, p. 1400 - 1419 (2015/03/04)

To develop novel neuroprotective agents, a library of novel arylalkenylpropargylamines was synthesized and tested for inhibitory activities against monoamine oxidases. From this, a number of highly potent and selective monoamine oxidase B inhibitors were identified. Selected compounds were also tested for neuroprotection in in vitro studies with PC-12 cells treated with 6-OHDA and rotenone, respectively. It was observed that some of the compounds tested yielded a marked increase in survival in PC-12 cells treated with the neurotoxins. This indicates that these propargylamines are able to confer protection against the effects of the toxins and may also be considered as novel disease-modifying anti-Parkinsonian agents, which are much needed for the therapy of Parkinson's disease.

Inhibition of monoamine oxidase by the R and S enantiomers of N-N-methyl-3-butyn-2-amine

Dostert, P,O'Brien, EM,Tipton, KF,Meroni, M,Melloni, P,Benedetti, M Strolin

, p. 45 - 52 (2007/10/02)

The chemical synthesis of the R-(+)- and S-(-)-enantiomers of N-N-methyl-3-butyn-2-amine is described.These compounds are derivatives of the mechanism-based irreversible monoamine oxidase inhibitor clorgyline in which a meth

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 4070-90-0